Nature Cancer

(The TQCC of Nature Cancer is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
The impact of the COVID-19 pandemic on cancer care363
Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis338
Pan-cancer image-based detection of clinically actionable genetic alterations336
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab246
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer237
Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer231
Cancer vaccines: the next immunotherapy frontier222
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma202
Overcoming therapy resistance in EGFR-mutant lung cancer197
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression177
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors166
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities164
Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome156
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer150
Fatty acid synthesis is required for breast cancer brain metastasis147
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity147
Cancer-associated fibroblasts in the single-cell era147
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity144
The metabolic landscape of RAS-driven cancers from biology to therapy137
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells134
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology132
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma131
Artificial intelligence in histopathology: enhancing cancer research and clinical oncology129
The current paradigm and challenges ahead for the dormancy of disseminated tumor cells128
Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology124
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer121
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer115
Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity114
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas113
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy110
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy110
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial109
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia104
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity102
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study102
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma101
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia101
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity99
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes95
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort94
The immuno-oncological challenge of COVID-1994
Translational advances in pancreatic ductal adenocarcinoma therapy92
Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients90
Applications of organoids for cancer biology and precision medicine90
The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response89
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment89
A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage88
Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer87
SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer84
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism82
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer82
Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in glioblastoma81
The cGAS–STING pathway and cancer80
Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis80
Targeting public neoantigens for cancer immunotherapy80
Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy78
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis76
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity75
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer74
Super enhancers define regulatory subtypes and cell identity in neuroblastoma74
Emerging strategies for treating metastasis74
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy73
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade73
CD4+ T cells in cancer73
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia72
The T cell differentiation landscape is shaped by tumour mutations in lung cancer72
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer70
Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors69
Age-associated mitochondrial DNA mutations cause metabolic remodeling that contributes to accelerated intestinal tumorigenesis68
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer67
Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF-β267
Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis64
Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors64
c-Rel is a myeloid checkpoint for cancer immunotherapy63
Dysregulation and therapeutic targeting of RNA splicing in cancer63
Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response63
Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration63
Engineering-enhanced CAR T cells for improved cancer therapy63
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study62
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients62
The present and future of PI3K inhibitors for cancer therapy62
GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision60
Crowdsourcing a crisis response for COVID-19 in oncology60
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets59
Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma58
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer57
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets55
ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 155
Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression54
Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer54
The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer54
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment54
Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain53
Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma53
Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization53
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment52
Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer52
The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome50
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study50
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer50
Bystander T cells in cancer immunology and therapy49
Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer49
The status of tumor mutational burden and immunotherapy49
A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance48
TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer47
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity46
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors46
Keap1 mutation renders lung adenocarcinomas dependent on Slc33a145
cfDNA methylome profiling for detection and subtyping of small cell lung cancers45
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology44
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment43
An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication43
Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors43
Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities43
Accelerating precision medicine in metastatic prostate cancer43
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia41
The deubiquitinase USP25 supports colonic inflammation and bacterial infection and promotes colorectal cancer41
Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells40
A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types40
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy40
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes40
Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance40
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response40
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer39
Moving pan-cancer studies from basic research toward the clinic39
Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis39
APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis39
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response38
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma38
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms38
KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming38
An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia37
Illuminating the noncoding genome in cancer37
The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription37
Metabolic adaptation of acute lymphoblastic leukemia to the central nervous system microenvironment depends on stearoyl-CoA desaturase37
Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy37
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect36
Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma36
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung35
Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors35
Cancer cell plasticity during tumor progression, metastasis and response to therapy34
Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia34
Advancing Cancer Therapy34
Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression34
Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs34
Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy33
Rethinking cancer clinical trials for COVID-19 and beyond33
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing33
Activation of p38α stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs33
Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways33
The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets32
Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer32
Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors32
Advances in antibody-based therapy in oncology32
Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress32
The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries31
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues31
Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia31
The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer31
Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia31
Deep learning links histology, molecular signatures and prognosis in cancer30
GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity30
Zeb2 drives invasive and microbiota-dependent colon carcinoma30
Delineating the evolutionary dynamics of cancer from theory to reality29
Discovery through clinical sequencing in oncology29
Cancer-associated fibroblasts employ NUFIP1-dependent autophagy to secrete nucleosides and support pancreatic tumor growth29
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations29
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting29
Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer29
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance29
A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling28
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice28
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders28
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade27
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse27
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer27
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes27
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling27